Aeterna Zentaris Inc.








Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise



Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macimorelin is currently marketed in the United States under the tradename Macrilen™through a license agreement with Novo Nordisk where Aeterna Zentaris receives royalties on sales. According to a commercialization and supply agreement, MegaPharm Ltd. will seek regulatory approval and then commercialize macimorelin in Israel and the Palestinian Authority. Additionally, upon receipt of pricing and reimbursement approvals, Aeterna expects that macimorelin will be marketed in Europe and the United Kingdom through a recently established license agreement with Consilient Health Ltd and Aeterna Zentaris will receive royalties on sales and other potential payments.

Market Cap: 17.9 Million

Primary Exchange: NASDAQ


Shares Outstanding: 4.86 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.789860847045482

Sector: Manufacturing

Industry: Biological Product (except Diagnostic) Manufacturing

Ethical Flags

Longest drawdown: 2658 trading days

From: 2013-01-29 To: 2022-09-27

Lowest Point:

Microcaps mostly among midday movers

via: SeekingAlpha at 2019-06-13 08:41:38:000

Gainers: Coda Octopus Group (NASDAQ: CODA ) +40% . Mmtec (NASDAQ: MTC ) +30% . Red Robin Gourmet Burgers (NASDAQ: RRGB ) +29% . DryShips (NASDAQ: DRYS ) +24% . Cemtrex (NASDAQ: CETX ) +21% . Ruhnn Holding Limited (NASDAQ: RUHN ) +21% . RH (NYSE: RH ) +20% . Aeterna Zentaris (N… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2015-11-20 100.0 1.0 100.0
Data provided by IEX Cloud